

ABBOTT PARK, IL 60064-6008

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/438,994	11/12/1999		JAMES J. FORT,	6487.US.01	1116
23492	7590	04/12/2006		EXAMINER	
ROBERT I		· <del></del>		VENKAT, JY	OTHSNA A
100 ABBOTT PARK ROAD				ART UNIT	PAPER NUMBER
DEPT. 377/A	AP6A			1615	

DATE MAILED: 04/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/438,994	FORT, ET AL.
Office Action Summary	Examiner	Art Unit
	JYOTHSNA A. VENKAT Ph. D	1615
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  136(a). In no event, however, may a reply be tim  will apply and will expire SIX (6) MONTHS from  a, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 30 J	s action is non-final. ince except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 1,13-15,18 and 22 is/are pending in t 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1,13-15,18 and 22 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	or election requirement.	
10) ☐ The drawing(s) filed on is/are: a) ☐ acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Ex	drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati prity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)	<b>0</b> □	(DTO 442)
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

Continued Examination Under 37 CFR 1.114

**DETAILED ACTION** 

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/30/06 has been entered.

Claims 1, 13-15, 18 and 22 are pending in the application and the status of the application is as follows:

Claim Rejections - 35 USC § 103

Claims 1, 13-15, 18 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combination of U. S. Patents 5,545,628 ('628) and 4,769,236 ('236).

The instant application is claiming a pharmaceutical composition comprising:

- 1. A solid dispersion of fenofibrate or a salt or ester there of
- 2. Hydroxypropylmethylcellulose (HPMC)
- 3. Polyethylene glycol (PEG) carrier

a method of preparing the composition and method of treating hyperlipidemia comprising administering the composition.

Patent '628 teaches pharmaceutical compositions containing fenofibrate. See col.1, lines 5-10, see col.2, lines 39-55 and see specially lines 50-51 where the patent teaches that HPMC is a suspension stabilizer which avoids the formation of fenofibrate crystals. This is same as claimed HPMC as the crystallization inhibitor. Seecol.2, lines 55-68, see col.3, lines 32-34,

Art Unit: 1615

where the patent suggests that PEG can be incorporated into the compositions. See col.4, lines 1-30 for the preparation and packing into the hard gelatin capsules, see col.7 lines 10-15 where the patent teaches HPMC with fenofibrate. See also pharmokinetical study. The difference between the patent and the instant application wher in the patent does not teach the limitation that the solvent is ethanol. However patent '236 teaches medicaments with a high degree of solubility and method for using their preparation using crystallization inhibiting agent which is Polyvinyl pyrrolidone (PVP) in PEG using ethanol as solvent. See col.1, lines 40-68 and col.3, and see example 1 where the patent teaches ethanol as the solvent. See also claims. Accordingly it would have been obvious to one of ordinary skill in the art to prepare fenofibrate composition taught by '628 and dissolve HPMC in PEG and use ethanol. One of ordinary skill in the art would be motivated to dissolve HPMC in PEG suggested by the patent '628 and also taught by '236 for PVP in PEG since patent '628 teaches the equivalency between HPMC and PVP as the suspension stabilizer and use ethanol with the reasonable expectation of success that high degree of solubility and dissolution of fenofibrate is obtained. This is a prima facie case of obviousness.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JYOTHSNA A. VENKAT Ph. D whose telephone number is 571-272-0607. The examiner can normally be reached on Monday-Friday, 10:30-7:30:1st Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, THURMAN K. PAGE can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/438,994 Page 4

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JYOTHSNA A VENKAT Ph. D

Primary Examiner Art Unit 1615

\*\*\*